BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) MyndRenew(TM) Earns TruShield Certification

BioAdaptives (OTC: BDPT) announced that MyndRenew(TM), the nighttime component of its MyndSystem(TM) cognitive health platform, has received TruShield Certified status, confirming compliance with anti-doping standards established by the World Anti-Doping Agency and the UFC. Combined with the previously certified MyndMed(TM) daytime formula, the company said MyndSystem(TM) is now a fully WADA-compliant 24/7 cognitive performance and recovery system for professional athletes.

The company said the certification strengthens its position in the sports nutrition market by supporting potential adoption among professional athletes while also targeting executives and active seniors. BioAdaptives said the milestone could enhance commercialization opportunities, strategic partnerships and broader market adoption as it expands the MyndSystem(TM) platform.

To view the full press release, visit https://ibn.fm/JNHRs

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based health and wellness products for humans and animals. Its formulations are grounded in published research on nutrition, adaptogens, and cellular health, with a focus on supporting normal physiological function.

For more information, please visit our website at www.bioadaptives.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Selects DRCARE247 as Telemedicine Partner

HealthLynked (OTCQB: HLYK) , a healthcare technology company focused on AI-powered patient engagement, care coordination…

22 hours ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data…

1 day ago

BioMedNewsBreaks — Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Preps ONC010 for Clinical Translation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations…

2 days ago

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast 

Quantum BioPharma (NASDAQ: QNTM) Co-Founder and Executive Co-Chair Anthony Durkacz returned to The BioMedWire Podcast…

2 days ago

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Moves VXA-222 Bispecific ADC to Next Development Stage

VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (“ADC”) program beyond the…

3 days ago

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Adds California Hub to Growing Pharmacy Network

Earth Science Tech (OTC: ETST) recently continued its expansion in the healthcare, pharmacy and telemedicine…

3 days ago